Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 306

1.

Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy.

Reed SA, Sandesara PB, Senf SM, Judge AR.

FASEB J. 2012 Mar;26(3):987-1000. doi: 10.1096/fj.11-189977. Epub 2011 Nov 18.

2.

Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia.

Silva KA, Dong J, Dong Y, Dong Y, Schor N, Tweardy DJ, Zhang L, Mitch WE.

J Biol Chem. 2015 Apr 24;290(17):11177-87. doi: 10.1074/jbc.M115.641514. Epub 2015 Mar 18.

3.

Sepsis increases the expression and activity of the transcription factor Forkhead Box O 1 (FOXO1) in skeletal muscle by a glucocorticoid-dependent mechanism.

Smith IJ, Alamdari N, O'Neal P, Gonnella P, Aversa Z, Hasselgren PO.

Int J Biochem Cell Biol. 2010 May;42(5):701-11. doi: 10.1016/j.biocel.2010.01.006. Epub 2010 Jan 13.

4.

C/EBPβ mediates tumour-induced ubiquitin ligase atrogin1/MAFbx upregulation and muscle wasting.

Zhang G, Jin B, Li YP.

EMBO J. 2011 Aug 16;30(20):4323-35. doi: 10.1038/emboj.2011.292.

5.

Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.

Sun R, Zhang S, Hu W, Lu X, Lou N, Yang Z, Chen S, Zhang X, Yang H.

Am J Physiol Cell Physiol. 2016 Jul 1;311(1):C101-15. doi: 10.1152/ajpcell.00344.2015. Epub 2016 Apr 27.

6.

Myostatin induces degradation of sarcomeric proteins through a Smad3 signaling mechanism during skeletal muscle wasting.

Lokireddy S, McFarlane C, Ge X, Zhang H, Sze SK, Sharma M, Kambadur R.

Mol Endocrinol. 2011 Nov;25(11):1936-49. doi: 10.1210/me.2011-1124. Epub 2011 Sep 29. Erratum in: Mol Endocrinol. 2015 Jan;29(1):153. Retraction in: Mol Endocrinol. 2016 Feb;30(2):274.

7.

Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study.

Yuan L, Han J, Meng Q, Xi Q, Zhuang Q, Jiang Y, Han Y, Zhang B, Fang J, Wu G.

Oncol Rep. 2015 May;33(5):2261-8. doi: 10.3892/or.2015.3845. Epub 2015 Mar 9.

PMID:
25760630
8.

Forkhead box O3 plays a role in skeletal muscle atrophy through expression of E3 ubiquitin ligases MuRF-1 and atrogin-1 in Cushing's syndrome.

Kang SH, Lee HA, Kim M, Lee E, Sohn UD, Kim I.

Am J Physiol Endocrinol Metab. 2017 Jun 1;312(6):E495-E507. doi: 10.1152/ajpendo.00389.2016. Epub 2017 Feb 28.

9.

SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth.

Lee D, Goldberg AL.

J Biol Chem. 2013 Oct 18;288(42):30515-26. doi: 10.1074/jbc.M113.489716. Epub 2013 Sep 3.

10.

Suppression of atrogin-1 and MuRF1 prevents dexamethasone-induced atrophy of cultured myotubes.

Castillero E, Alamdari N, Lecker SH, Hasselgren PO.

Metabolism. 2013 Oct;62(10):1495-502. doi: 10.1016/j.metabol.2013.05.018. Epub 2013 Jul 15.

PMID:
23866982
11.

The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors.

Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ.

Mol Cell. 2004 May 7;14(3):395-403.

12.

Signaling pathways perturbing muscle mass.

Glass DJ.

Curr Opin Clin Nutr Metab Care. 2010 May;13(3):225-9. Review.

PMID:
20397318
13.

mTORC1 promotes denervation-induced muscle atrophy through a mechanism involving the activation of FoxO and E3 ubiquitin ligases.

Tang H, Inoki K, Lee M, Wright E, Khuong A, Khuong A, Sugiarto S, Garner M, Paik J, DePinho RA, Goldman D, Guan KL, Shrager JB.

Sci Signal. 2014 Feb 25;7(314):ra18. doi: 10.1126/scisignal.2004809.

PMID:
24570486
14.

Smad3 induces atrogin-1, inhibits mTOR and protein synthesis, and promotes muscle atrophy in vivo.

Goodman CA, McNally RM, Hoffmann FM, Hornberger TA.

Mol Endocrinol. 2013 Nov;27(11):1946-57. doi: 10.1210/me.2013-1194. Epub 2013 Sep 3.

15.

Iron-induced skeletal muscle atrophy involves an Akt-forkhead box O3-E3 ubiquitin ligase-dependent pathway.

Ikeda Y, Imao M, Satoh A, Watanabe H, Hamano H, Horinouchi Y, Izawa-Ishizawa Y, Kihira Y, Miyamoto L, Ishizawa K, Tsuchiya K, Tamaki T.

J Trace Elem Med Biol. 2016 May;35:66-76. doi: 10.1016/j.jtemb.2016.01.011. Epub 2016 Jan 28.

PMID:
27049128
16.

Smad2/3 Proteins Are Required for Immobilization-induced Skeletal Muscle Atrophy.

Tando T, Hirayama A, Furukawa M, Sato Y, Kobayashi T, Funayama A, Kanaji A, Hao W, Watanabe R, Morita M, Oike T, Miyamoto K, Soga T, Nomura M, Yoshimura A, Tomita M, Matsumoto M, Nakamura M, Toyama Y, Miyamoto T.

J Biol Chem. 2016 Jun 3;291(23):12184-94. doi: 10.1074/jbc.M115.680579. Epub 2016 Apr 15.

17.
18.

Joint inflammation alters gene and protein expression and leads to atrophy in the tibialis anterior muscle in rats.

Ramírez C, Russo TL, Sandoval MC, Dentillo AA, Couto MA, Durigan JL, Salvini TF.

Am J Phys Med Rehabil. 2011 Nov;90(11):930-9. doi: 10.1097/PHM.0b013e31822dea3c.

PMID:
21959222
19.

Heart failure increases atrogin-1 and MuRF1 gene expression in skeletal muscle with fiber type-specific atrophy.

Carvalho RF, Castan EP, Coelho CA, Lopes FS, Almeida FL, Michelin A, de Souza RW, Araújo JP Jr, Cicogna AC, Dal Pai-Silva M.

J Mol Histol. 2010 Feb;41(1):81-7. doi: 10.1007/s10735-010-9262-x. Epub 2010 Mar 28.

PMID:
20349269
20.

IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression.

Yoshida T, Semprun-Prieto L, Sukhanov S, Delafontaine P.

Am J Physiol Heart Circ Physiol. 2010 May;298(5):H1565-70. doi: 10.1152/ajpheart.00146.2010. Epub 2010 Mar 12.

Supplemental Content

Support Center